Who
Ronald Asbury Andrews
Director
Company insider
Files Form 4 as: Director, Cerenome; Director, Precipio; Former CEO, Insight Molecular Diagnostics; Director, Oxford Immunotec Global; President, Medical Sciences, Life Technologies; Vice-Chairman and CEO, Clarient; Director, Cardiac Science.
In numbers
- Trades disclosed
- 133
- Buys
- 13
- Sells
- 0
- Bought
- $43.3M
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 3 Apr 2006
- Last trade
- 1 Oct 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 1 Oct 2026 | CNSY CerenomeMedical Devices | SEC FORM 4 Code M | —921 at $0.00 | filing |
| 1 Oct 2026filed 1 Oct 2026 | CNSY Cerenomeoption or derivative · Medical Devices | SEC FORM 4 Code M | —921 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus TherapeuticsMedical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Plus TherapeuticsMedical Devices | SEC FORM 4 Code M | —922 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —1,600 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,686 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | Plus Therapeuticsoption or derivative · Medical Devices | SEC FORM 4 Code A | —1,600 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PRPO Precipiooption or derivative · Life-science tools | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 15 Oct 2025filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,985568 at $17.58 | filing |
| 15 Oct 2025filed 20 Jan 2026 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,985568 at $17.58 | filing |
| 15 Oct 2025filed 16 Oct 2025 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,985568 at $17.58 | filing |
| 16 Jul 2025filed 18 Jul 2025 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,991676 at $14.78 | filing |
| 15 Apr 2025filed 17 Apr 2025 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,9961,785 at $5.60 | filing |
| 15 Jan 2025filed 16 Jan 2025 | PRPO PrecipioLife-science tools | SEC FORM 4 Code A | $9,9981,639 at $6.10 | filing |
News
Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyIMDX · tickerreport.com · 14 Oct 2026Reviewing Aktis Oncology (NASDAQ:AKTS) and Oncocyte (NASDAQ:IMDX)IMDX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Ronald Asbury Andrews; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.